Voyager Therapeutics (VYGR) Shares Outstanding (Weighted Average) (2014 - 2026)

Voyager Therapeutics has disclosed Shares Outstanding (Weighted Average) across 13 years of filings, most recently posting $59.5 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $59.5 million, up 1.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.5 million (up 1.96% YoY), and the FY2025 annual result was $58.7 million, up 1.77% from the prior year.
• Shares Outstanding (Weighted Average) came in at $59.5 million for Q1 2026 at Voyager Therapeutics, up from $58.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $59.5 million in Q1 2026 to a low of $38.0 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $57.1 million (2024), against an average of $49.6 million.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 41.23% in 2024 and climbed 1.31% in 2025, its largest moves.
• Voyager Therapeutics' Shares Outstanding (Weighted Average) stood at $38.4 million in 2022, then increased by 12.16% to $43.0 million in 2023, then jumped by 34.05% to $57.7 million in 2024, then grew by 1.77% to $58.7 million in 2025, then increased by 1.37% to $59.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $59.5 million (Q1 2026), $58.7 million (Q4 2025), and $58.6 million (Q3 2025), per Business Quant data.